Please assess the completion status of the following clinical trial:

Trial Title: S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary adenocarcinoma of the stomach, meeting the following criteria:~  * Newly diagnosed disease amenable to curative resection~ * Stage IB-III (T2-4)~* Measurable or nonmeasurable disease~* Enlarged lymph nodes outside of radiation fields must have preoperative biopsies~  * No positive lymph nodes outside of radiation fields~* No distant metastasis~* No gastroesophageal junction tumors~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* Absolute neutrophil count ≥ 1,500/mm³~* WBC ≥ 3,000/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal~* Albumin ≥ 3 g/dL~* Bilirubin normal~* No evidence of ischemic heart disease by EKG~* No coronary artery disease requiring active medical treatment~* No symptoms of angina~* No history of myocardial infarction~* No deep vein thrombosis within the past 12 months~* No pre-existing peripheral neuropathy~* No active pneumonia or inflammatory lung infiltrate~* No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for ≥ 5 years~* No clinically significant comorbid medical conditions that would prevent delivery of chemotherapy, radiotherapy, or the performance of surgery~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior and no concurrent sorivudine or brivudine~* No prior therapy for this malignancy, including chemotherapy, surgery, immunotherapy, or radiotherapy~* No prior coronary angioplasty or stenting~* No concurrent 2-dimensional or intensity-modulated radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy, Chemoradiation, Surgery (Type: EXPERIMENTAL): Chemotherapy: Oxaliplatin, 130 mg/m2, 2 hour IV infusion on Days 1 and 22; Capecitabine 850 mg/m2/dose, PO q 12 hours on Days 1-14 and 22-35 Chemoradiation: Capecitabine 650 mg/m2/dose, PO q 12 hours on days 43-77; Radiation therapy 180 cGy/day, 5 days/week beginning on Day 43.~Surgery: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).